Your holiday cookout could be killing you
Now, researchers say that eating any processed meat and other foods leaves Americans at a heightened risk for chronic conditions, including type 2 diabetes, ischemic heart disease, and colorectal cancer. The conditions result in the deaths of hundreds of thousands of people each year.
'Habitual consumption of even small amounts of processed meat, sugary drinks, and trans fatty acids is linked to increased risk of developing type 2 diabetes, ischemic heart disease and colorectal cancer,' Dr. Demewoz Haile, a research scientist at the Institute for Health Metrics and Evaluation in Seattle, told CNN this week.
Analyzing data from more than 60 previous related studies, the researchers found that eating processed meat – as little as just one hot dog a day – was associated with at least an 11 percent average increase in type 2 diabetes risk and a 7 percent increase in colorectal cancer risk.
Those who drank a sugar-sweetened beverage had an 8 percent average increase in type 2 diabetes risk and a 2 percent increase in ischemic heart disease risk.
The study builds on years of research tying processed foods to higher risks of obesity, heart disease, diabetes, and even cancer. The Dietary Guidelines recommend limiting these foods and drinks, including sodas, hot dogs, and sausages.
Although, researchers say it remains unclear exactly what aspects of processed foods pose potential health risks. It could be due to inflammation, Dr. Minyang Song, an associate professor of clinical epidemiology and nutrition at the Harvard T.H. Chan Schoo of Public Health, told CNN. He was not involved in the latest study.
Processed meats also often contain chemicals known as nitrates nitrites that serve as a preservative and give the meat its rosy color.
'Nitrates convert to nitrites, and in the stomach's acidic environment, nitrites interact with certain components concentrated in meat to form N-nitroso compounds, which are potential carcinogens,' according to Harvard Medical School.
Dr. Walter Willett, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health, points out that processed meats contain other additives and are high in sodium, which is a risk factor for high blood pressure and heart disease.
Dr. Ashkan Afshin, an assistant professor at the institute who was not a co-author of the new study, previously found that poor diet is responsible for more deaths globally than tobacco, high blood pressure, or any other health risk.
"Poor diet is an equal opportunity killer," he said in 2019. "We are what we eat and risks affect people across a range of demographics, including age, gender, and economic status."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
44 minutes ago
- The Guardian
Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The herbicide ingredient used to replace glyphosate in Roundup and other weedkiller products can kill gut bacteria and damage organs in multiple ways, new research shows. The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US. But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year. 'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic. Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure. Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen. The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining. Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said. The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ. Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail. The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment. Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere. Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients. 'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.' Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued. Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said. 'When you approach an issue from that lens there's only so much you will do,' he said.
The Guardian
2 hours ago
- The Guardian
Patients with ultra-rare diseases worry new FDA rules will leave them without treatment
US drug regulators have increasingly signaled a focus on faster approvals and rare diseases, but patients with ultra-rare ailments fear they are falling through the cracks, especially given challenges to conducting clinical trials. One drug, elamipretide, garnered a narrow recommendation from independent advisers for the US Food and Drug Administration (FDA), but the agency rejected the drug's application in May and recommended another potential pathway for approval. Patients and advocates worry about new rules on who may receive the medication during this process, and whether the drug will reach approval before the pharmaceutical company runs out of funding for it. It underscores the challenges of making progress on rare and ultra-rare diseases while also making sure treatments are safe and effective. Hope Filchak is a sassy four-and-a-half-year-old who loves swimming in the lakes and pools near her home in Gainesville, Georgia. She's also deaf and blind, with some functional vision in one eye and hearing with an aid in one ear. Hope was born with an extremely rare mitochondrial condition called MLS syndrome, of which there were only 64 documented cases in the US as of 2018. MLS syndrome, for Hope, causes a potentially life-threatening heart condition called cardiomyopathy, which can make her heart pump blood less efficiently. In February 2024, she started sleeping about 17 hours a day, and her speech began regressing. An echocardiogram revealed that Hope's heart function had dropped about 14 percentage points, into potentially hazardous territory. She then started taking elamipretide, an investigational drug for mitochondrial conditions. 'Pretty soon, honestly, she had a lot more energy,' her mother, Caroline Filchak, said. Most importantly, her heart stabilized. Hope's aunt, Anna Bower, said her niece's 'quality of life dramatically improved' and soon after, she was 'running, dancing, and playing' like any other child her age. First developed in 2004, elamipretide has a long history. Advocates for patients with Barth syndrome – another mitochondrial condition with about 150 known patients – asked Stealth BioTherapeutics to pick up the drug in 2014 and shepherd it through the regulatory process. Stealth submitted its first application to the FDA in 2019, and then it went through four different review divisions at the agency. In an October 2024 meeting of the FDA's cardiovascular and renal drugs advisory committee, patients and physicians spoke about the positive effects of the drug, and the advisers eventually voted 10-6 to recommend it. 'Patients and families saw the [advisory committee's] endorsement as an encouraging sign because the FDA almost always follows its recommendation,' Bower said in June. 'But last month, it didn't.' The FDA rejected the application in May. Internal FDA reviewers noted that the drug had not met its endpoint in phase 2 trials of 12 study participants. 'We don't feel like they looked at a totality of evidence where the patient's voice was heard in the decision,' Caroline Filchak said, who added that it's been difficult to measure the effectiveness of the drug because of how rare the disease is. The FDA did offer a new pathway to approval, Stealth said in a press release. That process takes at least eight months, though it can also take years. Stealth laid off 30% of its staff after the rejection. Advocates such as Filchak are worried the company will not be able to continue pursuing approval. 'If [the FDA] drag their feet like they have throughout this entire process, Stealth is not going to be able to continue operations,' she said. Under the new pathway, the medication is not available for infants. Stealth has said that 35 patients around the world are receiving the medication, and two-thirds of them are very sick infants. In a congressional hearing in late June, the Republican representative Earl L 'Buddy' Carter of Georgia asked Robert F Kennedy Jr, the secretary of the US Department of Health and Human Services, about treatments for rare mitochondrial conditions. Carter mentioned two young constituents with these conditions, including Hope Filchak. The children 'need your help in accessing life-saving medications', Carter said, promising to follow up with Kennedy after the hearing. For now, Hope has a three-month supply of the drug. 'For children like Hope, there are no other options,' Bower said. There are no FDA-approved medications like elamipretide, and there are no similar drugs in late-stage development. Caroline Filchak said that this administration 'does have a stated commitment to accelerating therapies for rare diseases. And it seems like this recent decision by the FDA doesn't align with that commitment.' Marty Makary, the FDA's commissioner, recently announced plans to accelerate approval for select drugs and companies. He has also floated the use of machine learning, often called AI, to review applications quickly. But there are already four ways for the FDA to expedite the review of new medications, and the approval speed is not the sticking point for drugs such as these, Filchak said. Elamipretide is an example of the difficulty of developing drugs for ultra-rare conditions – and for approving them based on clinical evidence, said Holly Fernandez Lynch, bioethicist at the University of Pennsylvania Perelman School of Medicine. 'It's not the poster child of FDA efficiency,' Fernandez Lynch said, noting the long time span and the four different review divisions at FDA. 'But it's also not the poster child of 'Oh my God, we have a drug that works amazingly well, and FDA is standing in the way, and why won't they just use their regulatory flexibility?'' The drug hasn't been approved yet because it hasn't met a pre-specified endpoint, Fernandez Lynch added: 'If the evidence doesn't support approval, if the systematic evidence collection doesn't show benefit, then FDA really can't approve it.' The biotech company is now resubmitting data on knee strength improvement as part of its new application. 'Of course, these patients have a need. Of course, they have an altered tolerance for risk and altered tolerance for uncertainty,' said Fernandez Lynch. 'That's the really devastating part of all of this. And it's really heartbreaking, but it does not mean the FDA should grant approval to a product that hasn't been demonstrated effective, because we really don't know that it works.' Approving a medication without this evidence could lead to issues developing other drugs for the same conditions, Fernandez Lynch said. 'People say, 'Well, what's the big deal? These patients have nothing. Just let them try it.' I get that. If I was that mom, I would do the same thing, right? But the FDA has to make judgments for the population,' she said. For Caroline Filchak, who works for a petroleum delivery company, she plans to continue advocating for her daughter and other affected children – and has even gotten the whole family involved. 'You don't, when you think about having a kid, think that you're going to be doing this, but you do what you've got to do for your kids,' she said, noting that she and her husband, Ben, took their seven-year-old son, Thomas, to the October meeting. 'We call him our baby advocate. Ever since that meeting, every night when he would say his prayers, he would pray that the FDA says 'yes'.'
Daily Mail
2 hours ago
- Daily Mail
Sami Sheen grabs some food in LA after revealing plans to remove breast implants
Sami Sheen enjoyed some refreshment at an Erewhon market in Calabasas, California, on Friday. The 21-year-old daughter of Denise Richards and Charlie Sheen was spotted leaving the market with a container of food. Two weeks ago the OnlyFans star revealed she plans to have her breast implants removed less than two years after she got them. She wrote that she's 'been experiencing health issues for nearly 2 years' with 'the weirdest symptoms.' Sami said that she 'finally discovered that I have breast implant illness,' adding, 'idk how I [hadn't] figured this out sooner but I'm so happy to finally have an answer.' She told her 202,000 followers: 'I'm hoping to get them removed asap so I can start feeling better.' And she asked: 'Pls lmk if you know of any good explant surgeons near LA.' Looking back at a picture of her pre-cosmetic surgery figure, Sami said; 'It's definitely gonna be hard going back to this size. not only physically, but mentally.' She lamented: 'I don't want to at all but i know i'll feel so much better once they are out. so i guess it's worth it.' She told fans: 'I posted about this on my TikTok but figured i would talk about it on here in case anyone else is experiencing the same thing. this is your sign to always put your health first!!!' The reality television star also noted that her sickness has affected her hair, writing in parentheses: 'Also I can't believe this is all my real hair, another thing that these implants took from me.' Someone asked Sheen what her symptoms are, which she detailed in a list. Chronic fatigue, headaches, acne, memory loss, brain fog, vertigo, joint pain, dry eyes, and mood swings were just some of the uncomfortable effects. Also listed were hair loss, allergies, skin rashes, severe anxiety, and sensitivity to temperature. Sami shared: 'BII often mimics certain autoimmune diseases, but I'm certain it's my implants because these symptoms started almost immediately after getting them done.' The influencer said she experiences 'nearly all of these symptoms every single day' and that 'it's exhausting'. The list goes on: Also listed were hair loss, allergies, skin rashes, severe anxiety, and sensitivity to temperature As recently as April, Sami said on TikTok that she planned to get another, larger boob job. She said at the time: 'They're finally fully dropped and settled in. I feel like I could've gone bigger and I really wish I went bigger. When the time comes to get them redone I'm definitely going bigger.' The star initially went under the knife in 2023 at age 19. 'I think I'm gonna go over the muscle so they look a little bit more natural,' she shared at the time.
